Browse the evidence

Exposure to environmental endocrine-disrupting chemicals (EDCs) is associated with adverse neurodevelopmental outcomes in children, including lower IQ, attention deficit, hyperactivity, and behavioral problems.

Reduce exposure to EDCs during pregnancy and childhood by avoiding plastic food storage, choosing natural personal care products, and filtering drinking water to protect developing brains.

Specific gut bacteria, including Bacteroides fragilis (via Polysaccharide A) and Faecalibacterium prausnitzii, can enhance the efficacy of cancer immunotherapy (ICB) by modulating T-cell responses and reducing inflammation.

For cancer patients undergoing immunotherapy, maintaining gut health through a diverse, fiber-rich diet may support the efficacy of treatment. While specific NGPs like B. fragilis and F. prausnitzii show promise, they are not yet standard clinical interventions. Consult with oncology teams before making significant dietary changes.

Curcumin extends the lifespan of model organisms (C. elegans, D. melanogaster, yeast, and mice) by modulating longevity signaling pathways (IIS, mTOR, PKA, FOXO) and enhancing antioxidant defenses (Nrf2/HO-1, SOD).

Curcumin, the active compound in turmeric, appears to activate cellular stress-response pathways (like Nrf2 and FOXO) that are linked to longevity in animal studies. While human lifespan extension isn't proven, its anti-inflammatory and antioxidant properties may support healthy aging. Consider incorporating turmeric/curcumin as part of a diet rich in polyphenols, potentially with black pepper or lipids to enhance absorption, though it is not a magic bullet for longevity.

In nonalcoholic fatty liver disease (NAFLD), lipotoxic hepatocytes release exosomes enriched with miR-192-5p, which activates pro-inflammatory M1 macrophages by inhibiting the Rictor/Akt/FoxO1 signaling pathway, thereby driving hepatic inflammation and disease progression.

This research highlights that liver fat accumulation (lipotoxicity) actively sends inflammatory signals to immune cells in the liver, worsening NAFLD. The primary actionable insight is that reducing hepatic fat (through caloric restriction, metabolic improvement, or specific dietary changes) may interrupt this exosomal miR-192-5p signaling, thereby reducing macrophage-driven inflammation and slowing disease progression.

The efficacy of GIP-GLP-1 co-agonists may be explained by biased agonism and altered receptor internalization, which prevents the desensitization seen with pure GIP agonists.

The superior effect of co-agonists like tirzepatide may be due to their specific molecular design, which alters how receptors are signaled and internalized, preventing the 'shut down' (desensitization) that occurs with pure GIP agonists.

Intermittent fasting worsens glucose tolerance and induces beta-cell death in mice with lysosomal dysfunction (LAMP2 deficiency) or impaired autophagosome formation (BECN1 deficiency).

If you have underlying cellular recycling defects, fasting might damage your pancreas. Consult a doctor before trying IF if you have known metabolic disorders.

Shorter telomeres in tumor tissue (breast, colon, prostate) are associated with advanced disease state, faster progression, and poorer survival, whereas leukocyte telomere length (LTL) shows inconsistent associations with cancer risk.

If you have cancer, shorter telomeres in the tumor tissue often signal a more aggressive disease. However, a blood test for telomere length (LTL) is not yet a reliable way to predict if you will get cancer, as research findings are inconsistent. Focus on proven risk reduction strategies rather than LTL testing for cancer prediction.

Tomatidine extends lifespan and healthspan in C. elegans by inducing mitophagy through the SKN-1/Nrf2 pathway.

Tomatidine, found in unripe tomatoes, may support healthy aging by clearing damaged mitochondria. However, current evidence is limited to worms and cell cultures. No human dosage or safety data exists yet. Do not self-prescribe high doses based on this research.

Overexpression of the mitochondrial deacetylase SIRT3 protects hepatocytes from lipotoxicity by promoting both macroautophagy (lipophagy) and chaperone-mediated autophagy (CMA) through the activation of the AMPK-ULK1 pathway.

This research highlights that maintaining healthy mitochondrial function and NAD+ levels (via exercise, fasting, or metabolic health) may support SIRT3 activity, which in turn helps the liver clear excess fat through autophagy. It suggests that strategies improving metabolic flexibility are more effective than targeting single enzymes in isolation.

CTRP9 is a potent cardioprotective adipokine that attenuates acute ischemia/reperfusion injury and mitigates pathologic ventricular remodeling post-MI, primarily via PKA-dependent pathways.

CTRP9 is a protein produced by the heart and fat that helps protect the heart after a heart attack. While not yet a standard treatment, maintaining metabolic health may support natural CTRP9 levels, which help reduce scarring and improve heart function after injury.

The splicing shift toward ING1a over ING1b promotes cellular senescence and prevents apoptosis, contributing to the maintenance of the senescent state.

No direct human intervention recommended.

For individuals with obesity who fail to lose ≥2% body weight in the first 4 weeks of intensive behavioral treatment, adding phentermine (15.0 mg/day) significantly increases 24-week weight loss compared to continuing behavioral treatment with placebo.

If you have been doing intensive lifestyle changes for a month and haven't lost at least 2% of your body weight, adding phentermine (15 mg daily) to your plan can significantly boost your weight loss results compared to sticking with lifestyle changes alone. This approach helps early non-responders achieve clinically meaningful weight loss (≥5%) much more effectively. Regular monitoring of blood pressure and heart rate is recommended due to potential side effects.

Subcutaneous semaglutide (2.0 mg or higher, once weekly) produces significant weight loss and cardiometabolic improvements in adults with overweight or obesity, with efficacy increasing in patients with Class II obesity and higher dosages.

If you have overweight or obesity, subcutaneous semaglutide taken once weekly at a dose of 2.0 mg or higher is a highly effective treatment for weight loss. It works best when combined with lifestyle changes (diet and exercise). You can expect significant weight loss (nearly 9 kg on average in this analysis) and improvements in waist circumference and BMI. Patients with more severe obesity (Class II) tend to lose more weight. While gastrointestinal side effects like nausea are common, serious side effects are rare. The once-weekly schedule is preferred for adherence and safety over daily dosing.

AMG 133 (maridebart cafraglutide), a bispecific molecule combining a GIP receptor antagonist with a GLP-1 receptor agonist, produces pronounced, dose-dependent weight loss and improves metabolic parameters in adults with obesity.

AMG 133 is a new injectable medication for obesity that works by targeting two gut hormones (GLP-1 and GIP). In early clinical trials, it caused significant weight loss (up to 14.5% of body weight) with a dosing schedule of just one injection every four weeks. While it can cause temporary nausea or vomiting, these side effects are usually mild and go away quickly. It is currently in clinical trials and not yet widely available.

High-intensity interval training (HIIT) significantly improves insulin sensitivity (fasting insulin and HOMA-IR) and cardiorespiratory fitness (VO2max) compared to moderate-intensity continuous training (MICT) in patients with diabesity.

If you have type 2 diabetes and are overweight, High-Intensity Interval Training (HIIT) may offer better improvements in insulin sensitivity and heart health than steady-state moderate exercise. HIIT involves short bursts of effort exceeding 80% of your max heart rate. It is time-efficient and can be adapted to your fitness level, making it a viable option even if you have physical limitations.

In patients with diabesity who have comorbidities, HIIT may significantly increase HDL cholesterol and further reduce HOMA-IR compared to MICT.

If you have type 2 diabetes, obesity, and other health conditions, HIIT might offer extra benefits for your 'good' cholesterol (HDL) and insulin resistance compared to moderate exercise. However, the evidence for this is very low certainty.

Among GLP-1 receptor agonists, Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide and Liraglutide in post-bariatric surgery patients, with the lowest rate of non-responders.

If you are using a GLP-1 agonist after bariatric surgery and not seeing enough results, ask your doctor about switching to or starting Tirzepatide. It is a newer dual-agonist that has shown greater weight loss and fewer non-responders compared to older options like Liraglutide or Semaglutide in recent studies. Note that data is currently limited to shorter-term studies.

Interval walking (alternating fast and slow speeds) improves glucose effectiveness and insulin sensitivity more effectively than continuous walking of matched energy expenditure in T2DM patients.

If you want to maximize the metabolic benefits of walking, try interval walking. Alternate 1 minute of brisk walking with 1 minute of normal walking for 60 minutes, 5 times a week. This method may improve your insulin sensitivity more than walking at a constant speed.

High-intensity interval training (HIIT) significantly improves cardiometabolic health markers—including glycemic control, insulin resistance, and lipid profiles—in patients with diabesity (Type 2 Diabetes and Obesity), even when body composition changes are minimal.

If you have Type 2 Diabetes and are overweight, High-Intensity Interval Training (HIIT) is a highly effective way to improve your blood sugar and cholesterol levels, even if the scale doesn't move much. Aim for short, intense bursts of exercise (like cycling or walking) 3 times a week for about 20-30 minutes, interspersed with rest. This approach targets your metabolic health directly and is considered safe for this population when prescribed correctly.

HIIT significantly improves lipid profiles (LDL, Triglycerides, Total Cholesterol) and insulin resistance (HOMA-IR) in patients with diabesity.

Focus on improving your insulin sensitivity and cholesterol through HIIT. This type of training has been shown to significantly lower your HOMA-IR score and improve LDL and Triglyceride levels compared to doing nothing, offering a powerful metabolic boost for those with diabesity.

Once-daily oral orforglipron significantly reduces body weight, BMI, and waist circumference compared to placebo in adult patients with obesity or overweight.

Take once-daily oral orforglipron as prescribed. Expect an average weight loss of about 6 kg compared to placebo, along with improvements in waist circumference and metabolic markers. Be prepared for common, non-severe gastrointestinal side effects like nausea, but note that serious adverse events are not increased. This is a viable alternative to injectable GLP-1s for those who prefer oral medication.

Postoperative use of GLP-1 receptor agonists (specifically liraglutide and semaglutide) effectively treats suboptimal clinical response (SoCR) and recurrent weight gain (RWG) after metabolic bariatric surgery, achieving weight loss comparable to or exceeding non-surgical populations.

If you regain weight after bariatric surgery, do not assume you must have another operation. GLP-1 medications (like semaglutide or liraglutide) are highly effective at reversing weight regain and improving metabolic health, often working better than in non-surgical patients.

Repeated dosing of smaller caffeine amounts (e.g., 2 mg/kg) is superior to a single large dose (e.g., 6-10 mg/kg) for maintaining performance during long-duration competitions with rest periods.

For long competitions with long breaks between lifts, don't take your whole caffeine dose at once. Split it into smaller doses (e.g., 2mg/kg) taken before each lift to keep the performance boost steady.

Eight weeks of moderate-intensity aerobic exercise training significantly reduces fasting plasma glucose in diabetic patients compared to conventional care alone.

If you have diabetes, adding moderate walking to your routine three times a week for 30-45 minutes can significantly lower your fasting blood sugar. Start with a 10-minute warm-up, walk at a pace that keeps your heart rate at 50-60% of its maximum, and finish with a 10-minute cool-down. This should be done in addition to your regular medical care.